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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objectives are to assess the efficacy and safety of herbal medicines for the treatment of patients with IBD.
B A C K G R O U N D
Description of the condition
The term ’Inflammatory bowel disease’ (IBD) describes a group
of inflammatory conditions affecting the colon and small intes-
tine (Langhorst 2005; Schmidt 2005; Xavier 2007). The most
common conditions are Crohn’s disease (CD) and ulcerative col-
itis (UC) (Xavier 2007). Although CD and UC differ, they may
present with similar symptoms, including abdominal pain, diar-
rhoea, rectal bleeding and weight loss (Xavier 2007). Extraintesti-
nal symptoms, such as anaemia and conditions due to malnutri-
tion, are highly prevalent in patients suffering from IBD (Stein
2010). A diagnosis of UC or CD is based on the defining symp-
toms (rectal bleeding, diarrhoea, abdominal pain), and verified by
colonoscopy and histopathology. Colonoscopy and the biopsy of
pathological lesions are required to confirm the presence of inflam-
mation in the intestine. The existence of inflammatory markers
in patients’ stool and blood samples also aid diagnosis and follow-
up.
Despite considerable research effort, the etiology and pathophysi-
ology of both UC and CD remain largely unknown (Khor 2011;
Xavier 2007). Both conditions appear to be caused by multifac-
torial processes, relating to individuals’ genetic predisposition, is-
sues of immune dysregulation, barrier dysfunction and altered mi-
crobial flora (Asakura 2007; Khor 2011; Kucharzik 2006; Xavier
2007; Kucharzik 2006).
In addition to physical symptoms, IBD can cause psycholog-
ical and social distress and reduces quality of life (Drossman
1989; Romberg-Camps 2010). Psychological factors have also
been shown to influence the course of these diseases emphasiz-
ing the need for a multimodal therapy approach to treatment
(Mawdsley 2005; Moradkhani 2013; Triantafillidis 2013).
Description of the intervention
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Herbal medicine refers to the use of plants, plant components
or preparations derived from them to cure or alleviate diseases,
pathological conditions or functions of the body or mind (Bone
2013;Kraft 2010; Saller 2002).Herbalmedicine is considered part
of complementary and alternative medicine (CAM) as defined by
the National Health Institute (NIH 2013). From this perspective,
isolated active ingredients or synthetic derivatives from plants, are
not considered to constitute herbal medicine (Saller 2002). Herbal
medicines can take different forms, including the use of powders,
teas, tablets, capsules, suppositories, extracts, lotions, fresh or dried
plants (NIH 2013).
Herbal medicine has been used for thousands of years (Langhorst
2006); knowledge about the effects of medicinal plants having
been passed down across the ages (Kraft 2010). The use of herbal
medicine is also commonplace, both in traditional medicine and
in home remedies. Most consumers assume that herbal medicine
is safe (Heinrich 2012), natural and gentle; with the possibility of
adverse effects being largely neglected (Ipsos MORI 2008). Ad-
verse effects may occur, with direct toxic effects from biologically
active constituents, or by contaminants and interactions between
herbal and traditional medications (Bent 2008).
How the intervention might work
The intervention consists of a variety of herbal preparations,
which may act through different mechanisms. Plants’ cellular
constituents include proteins, lipids or saccharides, intermedi-
ary metabolites such as organic acids and secondary cellular con-
stituents such as alkaloids, glycosides, flavonoids, saponins, tan-
nins and essential oils (Capasso 2003; Heinrich 2012). Whilst
the exact composition of ingredients in particular herbal drugs
remains unclear the secondary cellular constituents are generally
assumed to be pharmacologically relevant (Capasso 2003). Such
constituents may have anti-inflammatory, antiphlogistic or astrin-
gent properties, as well as exerting mucosal protective effects or
even influencing fecal microflora. Most herbal medicines, how-
ever, act via the combination and interaction of all of their active
ingredients (Heinrich 2012).
Herbal medications may also have psychological effects. Patients
who use CAM therapies often report that they help them to gain a
feeling of control over their diseases and treatments (Ipsos MORI
2008); perhaps thereby reducing their emotional distress and dis-
comfort. A placebo effect may also contribute to CAM therapies’
effectiveness.
Why it is important to do this review
The prevalence of CAM use in IBD patients ranges from 21 to
60% (Joos 2006; Joos 2011; Langhorst 2005; Li 2005; Weizmann
2012). Although a similar range of CAM therapies are used in-
ternationally, the use of single treatments differs widely between
countries and regions (Hilsden 2011). Probiotics and fish oils are
commonly used, with herbal medicines being used by 5 to 58% of
IBD patients (Hilsden 2011). Most patients combine CAM with
conventional medicine, rather than using it as an alternative treat-
ment option. Patients prior beliefs and expectations are therefore
likely to influence whether treatment effects are attributed to con-
ventional or CAM treatment (Langhorst 2005). This may help to
explain why surveys show that most patients treated with CAMdo
not report the amelioration of their symptoms (Fernández 2012).
IBDpatients’ reasons for usingCAMtherapies aremanifold.Many
patients report serious adverse effects from conventional treat-
ments (Weizmann 2012). Some patients seek to reduce their use of
steroid medications (Langhorst 2005). Other patients see conven-
tional therapies as ineffective (Hilsden 2011;Weizmann 2012), or
they are searching for an optimum treatment (Langhorst 2005).
Although most patients continue to use conventional medicine,
once they start CAM therapy (Hilsden 2011), few appear to advise
their treating physician of this fact (Ipsos MORI 2008), poten-
tially causing adverse effects from interactions with prescription
drugs.
While reviews and meta-analyses have been undertaken for pro-
biotics (Mallon 2007; Naidoo 2011), and fish-oils (Turner 2007;
Lev-Tzion 2014), high quality scientific evidence supporting the
use of herbal medicine is lacking (Joos 2011). A systematic review
evaluating the efficacy and safety of herbal medicines for the treat-
ment of IBD is vital to provide reliable data to inform decision
making by patients, physicians and CAM providers.
O B J E C T I V E S
The primary objectives are to assess the efficacy and safety of herbal
medicines for the treatment of patients with IBD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials examining the effects of herbal
medicines on IBD will be eligible for inclusion. Parallel group,
crossover trials, and dose-finding studies will be considered for
inclusion. Full text publications and abstract publications will be
eligible for inclusion if sufficient information about study design,
participants, interventions used and outcomes are reported.
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Types of participants
Trials that include participants of both genders and any age, with
active or quiescent UC or CD or both will be included. Data for
patients with CD or UCwill be analysed separately. No restriction
on the diagnostic procedures or settings used in the studies will
be applied. Studies that include participants with other disorders,
such as irritable bowel syndrome, will be excluded.
Types of interventions
Any form of herbal medicine used for the management of IBD or
IBD-related complaints, will be included, with the exception of
traditional Chinese medicine herbal preparations which are cov-
ered by a Cochrane review (Gan 2009). For the purpose of this
review, aroma therapy and homeopathy (mother tinctures only)
preparations will be regarded as herbal medicines. Preparations of
synthetic origin or those consisting only of plant derivatives will
be excluded (Heinrich 2012; Kraft 2010; Saller 2002). Special
emphasis will be paid to the quality of the herbal medicines used,
and we will differentiate between studies that use herbal medici-
nal products or botanicals. In the studies using herbal medicinal
products, the source of the therapeutic agents will be determined.
Preparations produced in the European Union, Switzerland and
Australia, will be differentiated from those produced elsewhere, as
the former have high standards of quality regulation for the man-
ufacture of herbal medicinal products, which the latter may not.
No restrictions will be applied regarding control groups. Studies
with placebo or no therapy controls, or any active control therapy
will be eligible for inclusion as comparators. The use of concomi-
tant medication or interventions will be allowed, if studies used
them in both groups.
Types of outcome measures
Primary outcomes
The primary outcomes will be clinical remission or relapse (di-
chotomous outcomes) as defined by the included studiesClinical
remission could be defined by several different clinical indices in-
cluding the Colitis Activity Index (CAI score of ≤ 4), the Ulcer-
ative Colitis - Disease Activity Index (UC-DAI score of ≤ 2), the
Rachmilewitz index (score of ≤ 4), the Mayo score (score of ≤
2), a Crohn’s Disease Activity Index (CDAI score of < 150), or
a Pediatric Crohn’s Disease Activity Index (PCDAI score of < 10
points).
Secondary outcomes
Secondary outcomes will include the following.
• Clinical response or improvement (dichotomous outcomes)
as defined by the included studies. Clinical improvement could
be defined by several different clinical indices. For example, a
decrease of > 70 points in the CDAI score from baseline, or a
decrease of 30% or 3 points on the Mayo score.
• Clinical disease activity (continuous outcomes) as measured
by various clinical indices. For example, the CDAI, PCDAI, the
CAI, Mayo score, or Harry-Bradshaw Index or any other
validated instrument.
• Endoscopic remission or improvement as defined by the
included studies. Endoscopic remission or improvement could
be defined by several different endoscopic indices. For example
the Crohn’s Disease Endoscopic Index of Severity (CDEIS) and
Simple Endoscopic Scale for Crohn’s Disease (SES-CD) or the
Rachmilewitz score or endoscopic index (EI), and endoscopic
activity index (EAI) for patients with UC.
• Endoscopic relapse as defined by the included studies.
• Health-related quality of life as measured by any validated
generic or disease-specific self-report scale such as the Short Form
36 Health Survey (SF-36), Short Form 12 Health Survey (SF-
12), the Inflammatory Bowel Disease Questionnaire (IBDQ),
and the EuroQol 5 Dimension Questionnaire (EQ-5D).
• Safety-related findings, for example reports of adverse
events, serious adverse events, withdrawals due to adverse events
or any abnormal laboratory findings.
Wheremore thanonemeasure is used for an outcome in a reviewed
study standard instruments will be preferred over novel ones and
multi-item instruments over single-item ones.
Search methods for identification of studies
Electronic searches
The following databases will be searched from inception to date:
(a) MEDLINE (via OVID);
(b) EMBASE (via OVID);
(c) Scopus (via ScienceDirect);
(d) The Cochrane Library (CENTRAL);
(e) CAMBASE (www.cambase.de);
(f ) AMED (Allied and Complementary Medicine Database, via
OVID);
(g) The homeopathy research institute database
(www.homeoinst.org/database); and
(h) TheWHOInternational Clinical Trials Registry Platform (IC-
TRP) search portal (http://apps.who.int/trialsearch/Default.aspx)
for all registered and ongoing trials. This database also covers all
entries from the Clinicaltrials.gov trial registry.
The search strategies to be used for each database are reported in
Appendix 1, Appendix 2, Appendix 3, Appendix 4, Appendix 5,
Appendix 6 and Appendix 7.
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Searching other resources
(a) Bibliographic screening.
We will check the reference lists of relevant trials or reviews to
identify further trials. A copy of the full article for each reference
reporting a potentially eligible trial will be obtained.
(b) Grey literature.
We will search the proceedings from the following congresses and
annual meetings for relevant abstracts (from 2005 to date):
• International Congress on Complementary Medicine
Research (ICCMR);
• European Congress for Integrative Medicine (ECIM);
• Digestive Disease Week (DDW);
• Annual Congress of the European Crohn’s and Colitis
Organisation (ECCO);
• United European Gastroenterology Week (UEGW); and
• Annual Scientific Meeting of the American College of
Gastroenterology (ACG).
We will contact the Society forMedicinal Plant and Natural Prod-
uct Research (GA), the Society for Phytotherapy (GPT) and the
Committee for Research into Natural Medicine to identify trials
on herbal medicine for patients with CD and UC.
Data collection and analysis
Selection of studies
Pairs of authors (RL/HCorRL/JL) will independently screen all of
the study titles and abstracts identified from the literature search.
Full papers of potentially eligible studies will then be read in full
by the same authors to determine whether the studies concerned
actually meet the review eligibility criteria. Disagreements will be
discussed and resolved with a third author (PK). The study se-
lection process will be documented using a PRISMA flow chart
(Moher 2009). Excluded studies will be recorded in a ’Character-
istics of excluded studies’ table. No language restrictions will be
applied. Studies in languages other than English, German, French,
Russian, Chinese, Norwegian, Swedish or Islandic will be profes-
sionally translated.
Data extraction and management
Pairs of authors (RL/PK or RL/KK) will independently extract
data from the included trials. We will enter the data in the ’Char-
acteristics of included studies’ table. All data will be checked for
accuracy by a fourth author (HC).Disagreements will be discussed
and resolved by agreement.
The following information will be extracted from the included
studies:
• Methods: study design, methods of participant allocation,
allocation concealment, blinding, drop-out rates and reasons for
drop-out;
• Participants: country of origin, setting, sample size,
diagnosis, diagnostic procedures, age, ethnicity;
• Intervention: type, dose, duration (for experimental and
control interventions), quality of preparations used; and
• Outcomes: type of outcomes, assessment instruments used,
assessment and follow-up intervals.
For trials with multiple publications, the earliest full journal publi-
cation will be considered the primary reference, however data will
be extracted from all of the related publications as appropriate.
Assessment of risk of bias in included studies
Two authors (RL,PK) will independently assess study quality us-
ing the Cochrane risk of bias tool (Higgins 2011). The following
domains will be assessed:
• Random sequence generation;
• Allocation concealment;
• Blinding of participants and personnel;
• Blinding of outcome assessment;
• Incomplete outcome data;
• Selective outcome reporting; and
• Other sources of bias.
Each domain will be judged as either:
• ’Low risk of bias’ if the requirements are adequately fulfilled;
• ’High risk of bias’ if the requirements are not adequately
fulfilled; and
• ’Unclear risk of bias’ if insufficient data for a judgement is
provided.
Details of the requirements and rules for each judgement can be
found in the Cochrane Handbook (Higgins 2011). The risk of
bias assessment will provide the basis for a judgement of the qual-
ity of evidence provided, based on the GRADE recommendations
(Brozek 2009; Guyatt 2008). We will use the GRADE approach,
to assess the overall quality of evidence for the primary outcome
and for selected secondary outcomes of interest. Outcomes from
the pooling of randomized trials start as high quality evidence, but
may be downgraded due to: (1) risk of bias, (2) indirectness (3)
inconsistency (unexplained heterogeneity) (4) imprecision (sparse
data) or (5) reporting bias (publication bias). We will use the
GRADE profiler software to generate the GRADE analysis and
summary of findings tables (GRADEpro).
Measures of treatment effect
Wewill calculate the risk ratio (RR) and corresponding 95%confi-
dence interval (CI) for dichotomous outcomes. The primary out-
comes, clinical remission and relapse will be classified as dichoto-
mous outcomes (in remission versus not in remission or relapse).
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A RR of > 1 for clinical remission, or a RR of < 1 for relapse will
denote the superiority of the experimental treatment. We will cal-
culate the mean difference (MD) and corresponding 95% CI for
continuous outcomes. Clinical disease activity and health-related
quality of life will be classified as continuous outcomes. When
studies use different instruments to measure the same construct
(e.g. SF-36 and IBDQ), we will calculate the standardized mean
difference (SMD) and corresponding 95%CI. Post-interventional
scores will be preferred over pre-post difference scores if available.
A negative MD will be taken to indicate the beneficial effects of
the experimental intervention over the control intervention for
disease activity, while a positive MD will be taken to indicate the
beneficial effects of the reviewed treatments for patients’ quality
of life. If the assessment instruments used are coded inversely, pa-
tients’ scores will be inverted by multiplying them by -1. Safety
outcomes will be classified as dichotomous (i.e. an adverse event
versus no adverse event).
Unit of analysis issues
Studies of CD and UC, and those studies that enrolled patients
with active or quiescent disease will be analysed separately. The
effects of each herb or herbal preparation will also be considered
separately.
In addition, studies with control groups using different types of
interventions (e.g. placebo or active treatment) will be analysed
separately and not combined in a single meta-analysis.
We will consider the following post-intervention measures if re-
peated outcome assessments are reported:
• For induction of remission studies the outcomes assessed
closest to 8 weeks post-treatment, but not less than 4 or more
than 16 weeks will be utilized for data analysis; and
• For maintenance of remission studies the outcomes assessed
closest to 12 months, but not less than 6 months post-treatment
will be utilized for data analysis.
Data from studies with non-standard designs will be handled ac-
cording to the Cochrane Handbook (Higgins 2011). For cross-
over trials, paired data will be analysed. If these data are not avail-
able, then data from the first active interventional phase alone will
be used. For studies presenting multiple, correlated comparisons,
all relevant experimental intervention groups (e.g. groups using
herbal preparations of varying doses) will be combined into a sin-
gle group and all control intervention groups (e.g. groups with
control medications of varying doses) will be combined into a sin-
gle control group.
Dealing with missing data
Where data are missing, we will attempt to contact the study au-
thors to obtain the missing data. If this approach fails, missing
data will be imputed from existing scores, such as standard er-
rors, confidence intervals or T-values as appropriate. Where nei-
ther of these approaches prove successful, average standard devia-
tions, from other reviewed studies, using the same outcome mea-
sures, will be substituted for missing standard deviations. Sensi-
tivity analyses will be conducted by excluding those studies where
missing data had to be imputed (see below). The potential impact
of missing data on the findings of the systematic review will be
discussed.
Assessment of heterogeneity
Heterogeneity will be assessed using theChi2 test (Cochran 1954).
A P value of ≤ 0.10 will be considered to indicate statistically
significant heterogeneity. The magnitude of heterogeneity across
studies will be assessed using the I2 statistic (Higgins 2003). We
will interpret the I2 values as follows: 0 to 24% indicates low het-
erogeneity across studies; 25 to 49% indicates moderate hetero-
geneity across studies; 50 to 74% indicates substantial heterogene-
ity across studies; and 75 to 100% indicates considerable hetero-
geneity across studies.
Assessment of reporting biases
Publication bias will be assessed by funnel plots if ten or more
studies are included in a meta-analysis. Funnel plots will be gener-
ated using the ReviewManager 5 software (RevMan 2014). These
plots will then be analysed visually. Generally symmetrical plots
indicate a low risk of reporting bias, while asymmetrical ones in-
dicate a high risk of such bias (Higgins 2011). However, other
elements may also influence the symmetry of funnel plots.
Bias introduced by multiple publications will be addressed by in-
cluding study results only once in a given analysis. If there is rea-
sonable doubt that two publications report results from the same
study attempts will be made to contact the trial authors to clar-
ify the issue. Location bias will be addressed by searching multi-
ple databases, including non-English language journals. Language
bias will be avoided by including studies irrespective of the lan-
guage of publication.
Data synthesis
Data will be pooled if at least two studies measure the same out-
come in patients with the same disease, using the same interven-
tion and control group. We will not pool data when the I2 value
is greater than 75%. We will calculate the pooled risk ratio and
corresponding 95% CI for dichotomous outcomes using a ran-
dom-effects model (inverse variance method, DerSimonian and
Laird). We will calculate the pooled MD and corresponding 95%
CI for continuous outcomes using a random-effects model. When
studies use different instruments to measure the same construct
(e.g. SF-36 and IBDQ), we will calculate the pooled SMD and
5Herbal medicines for the treatment of inflammatory bowel disease (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
corresponding 95% CI. All analyses will be performed using the
Review Manager 5 software (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
No subgroup analyses are planned. If statistical heterogeneity ap-
pears in any meta-analysis, sensitivity analyses will be used to ex-
plore possible reasons for this heterogeneity.
Sensitivity analysis
Studies with either inadequate random sequence generation or al-
location concealment’, a lack of blinding of the outcome assessors,
or a high risk of attrition bias, will be excluded from analysis, to as-
sess the robustness of point estimates. Further sensitivity analyses
will be performed by excluding studies where missing data were
imputed and studies that were unpublished or were published as
abstracts only.
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A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE and EMBASE (via OVID)
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
20. 18 not 19
21. exp Crohn disease/ or crohn*.mp.
22. (colitis and ulcerat*).mp.
23. ulcerative colitis.mp. or exp ulcerative colitis/
24. (inflammatory bowel disease* or IBD).mp.
25. extraintestinal.mp.
26. 21 or 22 or 23 or 24 or 25
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27. 20 and 26
28. Phytotherapy.mp. or phytotherapy.tw.
29. (herbal or herb).tw.
30. (Plants or medicinal therapy).mp.
31. Botanicals.tw.
32. Anthroposophy.mp.
33. Anthroposoph*.tw.
34. Homeopathy.mp.
35. Homeopath*.tw.
36. Aromatherapy.mp.
37. Aromatherap*.tw.
38. (Frankincense or boswellia serrata).tw.
39. Curcumin.tw.
40. Wheat grass.tw.
41. Aloe vera.tw.
42. (Barley or hordeum vulgare).tw.
43. Remed*.tw.
44. (Marigold or calendula).tw.
45. Belladonna.tw.
46. (Ginger or zingiber officinale).tw.
47. Valerian*.tw.
48. (Licorice root or glycyrrhiza).tw.
49. (Indian plantago or plantago ovate).tw.
50. (Meadowsweet or filipendula ulmaria).tw.
51. (Turmeric or curcuma longa or curcuma xanthorriza).tw.
52. (Tormentil or potentilla erecta or tormentilla erecta or potentilla tormentilla).tw.
53. Myrrh.tw.
54. (Blackcurrant or ribes nigrum).tw.
55. (Blueberry or vaccinium myrtillus or bilberry).tw.
56. (Goldenseal or hydrastis Canadensis).tw.
57. (Ground ivy or glechoma hederacea).tw.
58. (Gentian or gentiana lutea).tw.
59. (Yarrow or achillea millefolium).tw.
60. (Peppermint or mentha piperita or mentha arvensis).tw.
61. (Oak bark or quercus).tw.
62. (Common alchemilla or Alchemilla arvensis).tw.
63. (Chinese rhubarb or Rheum officinale or Rheum palmatum).tw.
64. (Agrimony or Agrimonia eupatoria or Agrimonia officinalis).tw.
65. (Fumitory or Fumaria).tw.
66. Burdock root.tw.
67. (Wormwood or artemisia absinthium).tw.
68. (Dandelion root or taraxacum officinale).tw.
69. Artichoke.tw.
70. (Flaxseed or linseed).tw.
71. (Slippery elm or ulmus).tw.
72. Chamomile.tw. OR Matricaria.tw.
73. Tea.tw.
74. Herbal decoct*.tw.
75. or/28-74
76. 27 and 75
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Appendix 2. Search strategy for Scopus (via ScienceDirect)
#1 TITLE-ABS-KEY (inflammatory bowel diseases)
#2 TITLE-ABS-KEY (colitis, ulcerative)
#3 TITLE-ABS-KEY (Crohn disease)
#4 #1 OR #2 OR #3
#5 TITLE-ABS-KEY (Phyto*)
#6 TITLE-ABS-KEY (herb*)
#7 TITLE-ABS-KEY (botanical)
#8 TITLE-ABS-KEY (Homeopath*)
#9 TITLE-ABS-KEY (plant)
#10 TITLE-ABS-KEY (Aromatherapy)
#11 TITLE-ABS-KEY (Frankincense) OR TITLE-ABS-KEY (boswellia serrata)
#12 TITLE-ABS-KEY (Curcumin)
#13 TITLE-ABS-KEY (Wheat grass)
#14 TITLE-ABS-KEY (Aloe vera)
#15 TITLE-ABS-KEY (Barley) OR TITLE-ABS-KEY (hordeum vulgare)
#16 TITLE-ABS-KEY (Marigold) OR TITLE-ABS-KEY (calendula)
#17 TITLE-ABS-KEY (Belladonna)
#18 TITLE-ABS-KEY (Ginger) OR TITLE-ABS-KEY (zingiber officinale)
#19 TITLE-ABS-KEY (Valerian)
#20 TITLE-ABS-KEY (Licorice root) OR TITLE-ABS-KEY (glycyrrhiza)
#21 TITLE-ABS-KEY (plantago)
#22 TITLE-ABS-KEY (Meadowsweet) OR TITLE-ABS-KEY (filipendula ulmaria
#23 TITLE-ABS-KEY (Turmeric) OR TITLE-ABS-KEY (curcuma)
#24 TITLE-ABS-KEY (Tormentil) OR TITLE-ABS-KEY (potentilla erecta) OR TITLE-ABS-KEY (tormentilla erecta) OR TITLE-
ABS-KEY (potentilla tormentilla)
#25 TITLE-ABS-KEY (Myrrh)
#26 TITLE-ABS-KEY (Blackcurrant) OR TITLE-ABS-KEY (ribes nigrum)
#27 TITLE-ABS-KEY (Blueberry) OR TITLE-ABS-KEY (vaccinium myrtillus) OR TITLE-ABS-KEY (bilberry)
#28 TITLE-ABS-KEY (Goldenseal) OR TITLE-ABS-KEY (hydrastis canadensis)
#29 TITLE-ABS-KEY (Ground ivy) OR TITLE-ABS-KEY (glechoma hederacea)
#30 TITLE-ABS-KEY (Gentian) OR TITLE-ABS-KEY (gentiana lutea)
#31 TITLE-ABS-KEY (Yarrow) OR TITLE-ABS-KEY (achillea millefolium)
#32 TITLE-ABS-KEY (Peppermint) OR TITLE-ABS-KEY (mentha piperita) OR TITLE-ABS-KEY (mentha arvensis)
#33 TITLE-ABS-KEY (Oak bark) TITLE-ABS-KEY (quercus)
#34 TITLE-ABS-KEY (Common alchemilla) OR TITLE-ABS-KEY (Alchemilla arvensis)
#35 TITLE-ABS-KEY (Chinese rhubarb) OR TITLE-ABS-KEY (Rheum officinale) OR TITLE-ABS-KEY (Rheum palmatum)
#36 TITLE-ABS-KEY (Agrimony) OR TITLE-ABS-KEY (Agrimonia eupatoria) OR TITLE-ABS-KEY (Agrimonia officinalis)
#37 TITLE-ABS-KEY (Fumitory) OR TITLE-ABS-KEY (Fumaria)
#38 TITLE-ABS-KEY (Burdock root)
#39 TITLE-ABS-KEY (Wormwood) OR TITLE-ABS-KEY (artemisia absinthium)
#40 TITLE-ABS-KEY (Dandelion root) OR TITLE-ABS-KEY (taraxacum officinale)
#41 TITLE-ABS-KEY (Flaxseed) OR TITLE-ABS-KEY (linseed)
#42 TITLE-ABS-KEY (Slippery elm) OR TITLE-ABS-KEY (ulmus)
#43 TITLE-ABS-KEY (Chamomile) OR TITLE-ABS-KEY (Matricaria)
#44 TITLE-ABS-KEY (Artichoke)
#45 #5 OR #6 OR … OR #44
#46 TITLE-ABS (randomized controlled trial)
#47 TITLE-ABS (randomized)
#48 TITLE-ABS (randomly)
#49 TITLE-ABS (random)
#50 TITLE-ABS (trial)
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#51 TITLE-ABS (groups)
#52 TITLE-ABS (placebo)
#53 TITLE-ABS (controlled)
#54 #46 OR #47 OR … OR #53
#55 #4 AND #45 AND #54
#56 #7 AND #55
Appendix 3. Search strategy for the Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees
#2 Ulcerative colitis
#3 Crohn disease
#4 #1 OR #2 OR #3
#5 MeSH descriptor: [Herbal therapy] explode all trees
#6 MeSH descriptor: [Homeopathy] explode all trees
#7#5 OR #6
#8 #4 AND #7
Appendix 4. Search strategy for CAMBASE
#1 Inflammatory Bowel Diseases
#2 ulcerative colitis
#3 Crohn disease
#4 #1 OR #2 OR #3
Appendix 5. Search strategy for AMED (via OVID)
#1 FT=Inflammatory bowel disease
#2 FT=ulcerative colitis
#3 FT=Crohn disease
Appendix 6. Search strategy for the homeopathy research institute database
#1 Inflammatory bowel disease
#2 ulcerative colitis
#3 Crohn disease
#4 #1 OR #2 OR #3
Appendix 7. Search strategy for the WHO International Clinical Trials Registry Platform
Advanced search:
1. Search terms:
2. Condition: Ulcerative colitis OR Crohn disease OR inflammatory bowel disease
Intervention: Phytotherapy OR herbal OR botanical OR homeopathy OR plant OR aromatherapy OR Frankincense OR boswellia
OR Curcumin OR Wheat grass OR Aloe vera OR Barley OR Marigold OR calendula OR Belladonna OR Ginger OR zingiber
officinale OR Valerian OR OR Licorice root OR glycyrrhiza OR plantago OR Meadowsweet OR filipendula ulmaria OR Turmeric
OR curcuma OR Tormentil OR potentilla erecta OR tormentilla erecta OR potentilla tormentilla OR Myrrh OR Blackcurrant OR
Blueberry OR vaccinium myrtillus OR bilberry OR Goldenseal OR hydrastis canadensis OR Ground ivy OR glechoma hederacea OR
Gentian OR gentiana lutea OR Yarrow OR achillea millefolium OR Peppermint OR mentha piperita OR mentha arvensis OR Oak
bark OR quercus OR Common alchemilla OR Alchemilla arvensis OR Chinese rhubarb OR Rheum officinale OR Rheum palmatum
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OR Agrimony OR Agrimonia eupatoria OR Agrimonia officinalis OR Fumitory OR Fumaria OR Burdock root OR Wormwood
OR artemisia absinthium OR Dandelion root OR taraxacum officinale OR Flaxseed OR linseed OR Slippery elm OR ulmus OR
Chamomile OR Matricaria OR Artichoke OR supplement
Recruitment Status: ALL
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